Loading clinical trials...
Loading clinical trials...
This study evaluates the amount of nicotine, cannabis, and toxicants linked to the use of nicotine e-cigarette and/or cannabis products in the blood and urine of young adult users as well as the cannabis and nicotine use behaviors of consumers.
PRIMARY OBJECTIVE: I. To evaluate differences in self-reported nicotine and cannabis use behaviors and biomarkers of exposure to toxicants and carcinogens by product use status, to generate effect sizes required to calculate sample sizes needed for a larger study.
Age
18 - 25 years
Sex
ALL
Healthy Volunteers
Yes
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Start Date
April 3, 2025
Primary Completion Date
September 1, 2028
Completion Date
September 1, 2028
Last Updated
October 3, 2025
150
ESTIMATED participants
Effectiveness of different recruitment approaches
OTHER
Choice of study completion locations
OTHER
Cannabis Engagement Assessment
OTHER
E-cigarette dependence Scale
OTHER
Lead Sponsor
Roswell Park Cancer Institute
NCT06264154
NCT07111234
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07039292